News

Published on 24 Dec 2024 on The Motley Fool · via AOL

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into...


Article preview image

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI)...

NASDAQ.SNY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into...

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI...

The Motley Fool · via AOL 24 Dec 2024

The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and...

(You can read the full research report on United-Guardian here >>>) Why Haven't You Looked at Zac...

Zacks · via Yahoo Finance 24 Dec 2024

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to...

Zacks · via Yahoo Finance 23 Dec 2024

Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we a...

Insider Monkey · via Yahoo Finance 23 Dec 2024

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrou...

TipRanks · via Yahoo Finance 21 Dec 2024

Cytokinetics stock rises on Sanofi’s rights acquisition By Investing.com

Shares of Cytokinetics (NASDAQ:CYTK), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company...

Investing.com 20 Dec 2024

Why Cytokinetics Stock Was a Nearly 5% Winner Today

This is a drug targeting heart disease hypertrophic cardiomyopathy (HCM) that was developed by Cy...

Motley Fool · via Yahoo Finance 20 Dec 2024

Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com

Shares of Cytokinetics (NASDAQ:CYTK), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company...

Investing.com 20 Dec 2024

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage...

Zacks · via Yahoo Finance 18 Dec 2024

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?

Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than avera...

Zacks · via Yahoo Finance 18 Dec 2024